Investigating Alykl Hydoxylation in P450-can Using EVB

Shen Ye

Abstract

Cytochrome P450s are a superfamily of haemoproteins^1-3 which catalyse the oxidation of organic molecules⁴. One P450 enzyme studied for its hydroxylation mechanism is P450_cam (CYP101) from the Pseudomonas putida bacteria, whose crystal structure (1DZ9) was solved by Schlichting et al.⁵. The active form of P450_cam contains an oxyferryl species known as compound I(CPDI), where the iron has a formal oxidation state of Fe(V) ^{6, 7} in the plane of a porphyrin ring with a protruding oxygen atom. This oxygen atom is a tremendously potent oxidising agent and can readily abstract a hydrogen of a C-H bond from non-activated hydrocarbons with potentially high regioselectivity[REF].

Acknowledgements

The author would like to thank:

• Patrick von Glehn
• Dr Richard Lonsdale
• Professor Adrian Mulholland
• Professor Jeremy Harvey
• Professor Neil Allan

Table of Contents

Abstract

Acknowledgements

Table of Contents

Part I – Literature Review

An introduction to haem oxygenases

Cytochrome P450 enzymes

P450 catalytic cycle

P450cam

An introduction to CHARMM and EVB

Part II Methodology

Part I – Literature Review

An introduction to haem oxygenases

After hydrogen and helium, oxygen is the third most abundant chemical element in the universe⁸ and makes up 20.9% of Earth’s atmosphere⁹. Oxygen accounts for 65% of the mass in humans⁸ as it is found in all biological systems including carbohydrates, proteins, lipids and water. Oxygen occurs in the atmosphere as dioxygen, with a triple ground state where the two unpaired electrons are occupying two degenerate molecular orbitals¹⁰. This makes incorporating atmospheric oxygen into organic molecules (predominantly singlet species) extremely difficult as it would be a spin forbidden process.

Haem oxygenases are enzymes containing a prosthetic haem cofactor, an iron atom held by a porphyrin ring. Haem B is the most common prosthetic haem group, consisting of a protoporphyrin IX ring bound to the iron. It is most commonly found in the human body inside haemoglobin and myoglobin¹¹, playing a major role when it comes to binding atmospheric dioxygen. There are two groups of haem oxygenases, monooxygenases and dioxygenases, one reacts using a single oxygen atom and the other using both oxygen atoms.

The haem B cofactor and the apoenzyme are synthesised separately in different parts of a cell and they are connected via ligation to the iron atom on the proximal face¹². The protoporphyrin ring is a tetrapyrrole macrocycle synthesised from basic biological precursors including succinyl CoA and the most basic amino acid, glycine¹³. Ferrochelatase coordinates the iron atom to the protoporphyrin, producing haem B¹⁴. In cytochrome P450 enzyme the iron is ligated to a proximal cysteine residue via the sulphur atom¹⁵, however in some other oxygenases and other haemoproteins such as haemoglobin and myoglobin the iron is coordinated to a proximal histidine residue¹⁶.

In monooxygenases one of the dioxygen atoms is converted to H₂O and the other is commonly inserted into an aliphatic position of the substrate, producing a hydroxyl group by oxidation of reducing agents such as NADH and NAD(P)H^{17, 18}. The most studied haem-containing monooxygenases are the superfamily of cytochrome P450 enzymes due to their large diversity and versatility^{19, 20}.

Cytochrome P450 enzymes

Cytochrome P450 enzymes (CYP) were first discovered by Axelrod²¹ and Brodie et al.²² in 1955 when they observed the oxidation of xenobiotic compounds in the endoplasmic reticulum of the liver, but the enzymes responsible were still unknown until 1962. Klingenberg²³ and Garfinkel²⁴ found a carbon monoxide binding pigment in the rat and pig livers, respectively, which had an absorption maximum at 450 nm. The CO molecule was bound to the centre of the haem and its 450 nm absorption maximum²⁵ is prevalent in all CYPs^26-28, an electron spin resonance spectrum identified this enzyme was a low spin haemoprotein²⁹. This 450 nm Soret peak is the origin of the name P450. The superfamily of CYPs contain over a thousand haem monooxygenases³⁰ and are present in nearly all living organisms and even viruses, a well-known exception is Escherichia coli^{4, 19} which is widely used to investigate CYPs by sequence insertion into plasmids and allow the E. coli to express the genes^{31, 32}. CYPs typically contain approximately 500 amino acids, the cysteine residue which ligates to the haem group is located near the carboxy-terminus and the amino-terminus region of CYPs are rich in hydrophobic residues and is believed to be responsible for binding the enzymes to the lipid bilayers of cells³³.

CYPs in mammals are a crucial part of catalysing the metabolism of organic compounds and the biosynthesis of steroid hormones³⁴, such as oestrogen and testosterone, and are able to perform hydroxylation, epoxidations and other oxidation reactions at physiological temperatures³⁵ extremely selectively. Such reactions when performed uncatalysed tend to require extremely high temperatures⁵. CYPs are tremendously versatile, they’re able to catalyse a wide range of foreign hydrophobic compounds, which helps to protect the organism if they have ingested potentially harmful substances including toxins and carcinogens³⁶. This ability is often called “xenobiotic metabolism”³⁷.

There is a system for the nomenclature of P450 enzymes, which is “CYP” followed by a number, a latter and another number, e.g. CYP2J2. The first number relates to the family of the CYP, where all the CYPs in the family share a sequence identity of 40% or greater. The letter afterwards corresponds to the subfamily, where the CYPs in the subfamily share a sequence identity of 55% of greater. The final number is a label where all CYPs with this label share a sequence identity of 97% or greater³⁸. CYPs with the same label are known as isoforms.

Humans have 57 different CYP isoforms divided into 18 families and 42 subfamilies³⁴. Most of the isoforms are found on membranes, including the inner membrane of mitochondria, the endoplasmic reticulum and the cell membrane. They all differ in roles but the processes they all catalyse are similar and a few are crucial for catalysing more than once process. For example CYP 17A1 is located in the endoplasmic reticulum and is shown to be both a hydrolase and lyase, a key enzyme in the biosynthetic pathway of steroids including oestrogens and progestins³⁹. The most researched area of CYPs is the drug metabolising CYPs in the human hepatic system such as 3A4⁴⁰, 2C9⁴¹, 2D6⁴², 2E1⁴³, 1A2 and 2C19⁴⁴. These CYPs are responsible for the xenobiotic metabolism against infested foreign compounds, breaking them down into more readily soluble products to aid excretion through the urinary system⁴⁵. For this reason, a good understanding of the metabolic pathway of organic molecules inside the body allows drug development to invent new methods of bioactivation of inert but bioavailable forms of an active compound, where the ingested compound is inactive but gets metabolised into the active form inside the body. The versatility of CYPs can sometimes cause unexpected side-effects in metabolising pharmaceutical drugs, for example some bioactive compounds in grapefruit juice have been found to inhibit CYP catalysed metabolism of certain cardiovascular drugs, causing an increased blood concentration of the bioactive drug, thus leaking to a risk of overdose^{46, 47}.

P450_cam

P450cam was the first CYP to have its three-dimensional structure determined. It displays a high region- and stereoselectivity when catalysing the hydroxylation of camphor, only the exo-hydroxyl at C5 position is produced. Despite the extensive research into P450s, there are still certain details of the mechanism which are not fully understood.

References

1.T.K. D. R. Nelson, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzales, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda and D. W. Nebert DNA Cell Biol, 1993. 12(1): p. 1-51.

2.C. Loannides and D. Parke, Drug metabolism reviews, 1990. 22(1): p. 1-85.

3.A. Altun, S. Shaik, and W. Thiel, Journal of the American Chemical Society, 2007. 129(29): p. 8978-8987.

4.P. Danielson, Current drug metabolism, 2002. 3(6): p. 561-597.

5.I. Schlichting, J. Berendzen, K. Chu, A.M. Stock, S.A. Maves, D.E. Benson, R.M. Sweet, D. Ringe, G.A. Petsko, and S.G. Sligar, Science, 2000. 287(5458): p. 1615-1622.

6.D. Dolphin, A. Forman, D. Borg, J. Fajer, and R. Felton, Proceedings of the National Academy of Sciences, 1971. 68(3): p. 614-618.

7.J.E. Penner-Hahn, K. Smith Eble, T.J. McMurry, M. Renner, A.L. Balch, J.T. Groves, J.H. Dawson, and K.O. Hodgson, Journal of the American Chemical Society, 1986. 108(24): p. 7819-7825.

8.R. Chang, Chemistry. 9th Edition ed. 2007: McGraw-Hill.

9.A. Murphy, Plasma Chemistry and Plasma Processing, 1995. 15(2): p. 279-307.

10.T.F. Slater, Free radical mechanisms in tissue injury, in Cell Function and Disease. 1988, Springer. p. 209-218.

11.A.R. Fanelu, E. Antonini, and A. Caputo, Advances In Protein Chemistry, 1964. 19: p. 73.

12.H.S. Marver, D.P. Tschudy, M.G. Perlroth, and A. Collins, Science, 1966. 154(3748): p. 501-503.

13.F.J. Leeper, Natural Products Reports, 1983. 19: p. 1137-1161.

14.T. Yoon and J. Cowan, Journal of Biological Chemistry, 2004. 279(25): p. 25943-25946.

15.A.W. Munro, D.G. Leys, K.J. McLean, K.R. Marshall, T.W. Ost, S. Daff, C.S. Miles, S.K. Chapman, D.A. Lysek, and C.C. Moser, Trends in biochemical sciences, 2002. 27(5): p. 250-257.

16.D.F. Brook and P.J. Large, European Journal of Biochemistry, 1975. 55(3): p. 601-609.

17.M.H.M. Eppink, C. Bunthof, H.A. Schreuder, and W.J.H. van Berkel, FEBS Letters, 1999. 443(3): p. 251-255.

18.S. Harayama, M. Kok, and E.L. Neidle, Annual Review of Microbiology, 1992. 46(1): p. 565-601.

19.A. Sigel, H. Sigel, and R.K. Sigel, The ubiquitous roles of cytochrome P450 proteins: metal ions in life sciences. Vol. 10. 2007: John Wiley & Sons.

20.P.R.O. De Montellano, Cytochrome P450: structure, mechanism, and biochemistry. 2005: Springer.

21.J. Axelrod, Journal of Pharmacology and Experimental Therapeutics, 1956. 117(3): p. 322-330.

22.B.B. Brodie, J. Axelrod, J.R. Cooper, L. Gaudette, B.N. La Du, C. Mitoma, and S. Udenfriend, Science, 1955. 121(3147): p. 603-604.

23.M. Klingenberg, Archives of biochemistry and biophysics, 1958. 75(2): p. 376-386.

24.D. Garfinkel, Archives of biochemistry and biophysics, 1958. 77(2): p. 493-509.

25.R.W. Estabrook, D.Y. Cooper, and O. Rosenthal, Biochemische Zeitschrift, 1962. 338: p. 741-755.

26.T. Omura and R. Sato, J. Biol. Chem., 1962. 237: p. 1375-1376.

27.T. Omura and R. Sato, J. Biol. Chem., 1964. 239: p. 2370-2378.

28.T. Omura and R. Sato, J. Biol. Chem., 1964. 239: p. 2379-2385.

29.Y. Hashimoto, T. Yamano, and H. Mason, Journal of Biological Chemistry, 1962. 237(12): p. PC3843-PC3844.

30.B. ÄŒrešnar and Š. Petrič, Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2011. 1814(1): p. 29-35.

31.E.M.J. Gillam, Z.Y. Guo, and F.P. Guengerich, Archives of Biochemistry and Biophysics, 1994. 312(1): p. 59-66.

32.A. Parikh, E.M. Gillam, and F.P. Guengerich, Nature biotechnology, 1997. 15(8): p. 784-788.

33.J.A. Hasler, R. Estabrook, M. Murray, I. Pikuleva, M. Waterman, J. Capdevila, V. Holla, C. Helvig, J.R. Falck, and G. Farrell, Molecular Aspects of Medicine, 1999. 20(1): p. 1-137.

34.D.W. Nebert and D.W. Russell, The Lancet, 2002. 360(9340): p. 1155-1162.

35.D. Harris, G. Loew, and L. Waskell, Journal of Inorganic Biochemistry, 2001. 83(4): p. 309-318.

36.P. Anzenbacher and E. Anzenbacherova, Cellular and Molecular Life Sciences CMLS, 2001. 58(5-6): p. 737-747.

37.X. Ding and L.S. Kaminsky, Annual review of pharmacology and toxicology, 2003. 43(1): p. 149-173.

38.R. Lonsdale, Cytochrome P450 Reactivity and Specificity from QM/MM Modelling, 2009, School of Chemistry, University of Bristol.

39.R. Zuber, E. Anzenbacherova, and P. Anzenbacher, Journal of cellular and molecular medicine, 2002. 6(2): p. 189-198.

40.J.S. Markowitz, J.L. Donovan, C.L. DeVane, R.M. Taylor, Y. Ruan, J.-S. Wang, and K.D. Chavin, Jama, 2003. 290(11): p. 1500-1504.

41.J.O. Miners and D.J. Birkett, British journal of clinical pharmacology, 1998. 45(6): p. 525-538.

42.A. Gaedigk, M. Blum, R. Gaedigk, M. Eichelbaum, and U. Meyer, American journal of human genetics, 1991. 48(5): p. 943.

43.G. Blakey, J. Lockton, J. Perrett, P. Norwood, M. Russell, Z. Aherne, and J. Plume, British journal of clinical pharmacology, 2004. 57(2): p. 162-169.

44.V. Uttamsingh, C. Lu, G. Miwa, and L.-S. Gan, Drug metabolism and disposition, 2005. 33(11): p. 1723-1728.

45.J.F. Rogers, A.N. Nafziger, and J.S. Bertino Jr, The American journal of medicine, 2002. 113(9): p. 746-750.

46.D.G. Bailey and G.K. Dresser, American journal of cardiovascular drugs, 2004. 4(5): p. 281-297.

47.H. Hirashima, N. Uchida, I. Fukazawa, S. Ishigaki, E. Uchida, and H. Yasuhara, Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2006. 37(3): p. 127-133.